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Abstract G1 phase cell cycle proteins, such as cyclin-de-
pendent kinase 6 (Cdk6) and its activating partners, the
D-type cyclins, are important regulators of T-cell devel-
opment and function. An F-box protein, called F-box only
protein 7 (Fbxo7), acts as a cell cycle regulator by
enhancing cyclin D-Cdk6 complex formation and stabilis-
ing levels of p27, a cyclin-dependent kinase inhibitor. We
generated a murine model of reduced Fbxo7 expression to
test its physiological role in multiple tissues and found that
these mice displayed a pronounced thymic hypoplasia.
Further analysis revealed that Fbxo7 differentially affected
proliferation and apoptosis of thymocytes at various stages
of differentiation in the thymus and also mature T-cell
function and proliferation in the periphery. Paradoxically,
Fbxo7-deficient immature thymocytes failed to undergo
expansion in the thymus due to a lack of Cdk6 activity,
while mature T cells showed enhanced proliferative
capacity upon T-cell receptor engagement due to reduced
p27 levels. Our studies reveal differential cell cycle regu-
lation by Fbxo7 at different stages in T-cell development.
Keywords Fbxo7  T-cell development  Cell cycle 
Cdk6  p27
Introduction
Fbxo7 (F-box only protein 7) is a multi-functional protein
with remarkable tissue-specific effects and is of clinical
relevance in a variety of human pathologies, ranging from
Parkinson’s disease and blood disorders to cancer [1–3].
Fbxo7 is a member of the 69 F-box domain-containing
protein family, which function as substrate-docking sub-
units of SCF (Skp1-Cullin1-F-box)-type E3 ubiquitin
ligases [4–8]. These ligases act at the last transference step
in the modification of protein substrates by ubiquitin.
Substrates of SCFFbxo7 ligase include the kinetochore
protein HURP, NF-jB signalling regulators c-IAP and
TRAF2, and NRAGE, a protein involved in apoptosis
arising from nerve growth factor signalling [9–12]. In
addition to this canonical function, Fbxo7 has other well-
documented SCF-independent roles, including acting as a
cell cycle regulator in two ways: first, by interacting
directly with the G1 phase kinase Cdk6, promoting its
binding activation by D-type cyclins, and second, by
binding and stabilising the levels of cyclin-dependent
kinase inhibitor (CDKI), p27 [1, 13, 14]. This cell cycle
regulatory role of Fbxo7 is important in erythropoiesis, and
we have reported that the reduction of Fbxo7 in a mouse
causes anaemia, caused by a failure of differentiating
erythroblasts to withdraw from the cell cycle due to
insufficient levels of p27 [15, 16]. Multiple GWAS studies
reinforce the importance of Fbxo7 in red blood cell (RBC)
biology as SNPs in FBXO7 are associated with clinically
relevant RBC parameters [17–20]. In addition to GWAS
studies of the blood, similar studies on families with
pedigrees showing cases of the early onset Parkinson’s
disease revealed the homozygous inheritance of point
mutations in FBXO7 to be causative [21–23]. Subse-
quently, also named PARK15, Fbxo7 was found to interact
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directly with two other genes mutated in Parkinson’s dis-
ease, PINK1/PARK6, and Parkin/PARK2, to promote
mitophagy [24]. Pathogenic point mutations map to func-
tional domains in Fbxo7 including T22M within its
N-terminal ubiquitin-like (Ubl) domain that interacts
directly with Parkin; R378G adjacent to the F-box domain,
which reduces its ability to form an E3 ligase complex; and
R498X within one of its substrate-recruiting domains near
the end of the protein [3]. Collectively, these mutations
point to multiple defects in Fbxo7’s many functions as
contributing to neurodegeneration. However, as neurons
are post-mitotic, this is unlikely to involve its cell cycle
regulatory activity.
In addition to its cell cycle regulatory function in
erythropoiesis, we reported that Fbxo7 has an anti-pro-
liferative function and a role in promoting the
maturation of precursor B lymphocytes, caused by sta-
bilising p27 levels and inhibiting S phase kinase activity
[16]. G1 phase cell cycle proteins are known to play key
roles in regulating proliferation and maturation of T
lymphocytes in the thymus. Two of the three D-type
cyclins are strongly expressed, cyclin D2 before the
rearrangement of T-cell receptor (TCR) b, and cyclin
D3 afterwards. These cyclins appear to act primarily
through activation of Cdk6, rather than Cdk4. In support
of its non-redundant role, Cdk6 knock-out mice have a
striking reduction in thymus size and show a block in
differentiation at the DN3 stage along with impaired
proliferation at the DN2 and DN3 stages [25, 26].
Cyclin D3 null mice also have a small thymus, due to
deficient expansion of immature thymocytes at the DN4
stage [27]. Despite cyclin D2 being highly expressed at
DN1 to DN3 stages, it is dispensable for T-cell differ-
entiation as cyclin D2 knock-out mice do not show
thymic defects, which the authors of that study attrib-
uted to compensation by cyclin D3 [28]. Cyclin D3 and
Cdk6 are both proto-oncogenes in T cells, and are
overexpressed in T-cell malignancies, like T-ALL and
T-cell lymphoma [27]. Moreover, they are thought to
function as critical downstream transducers of other
oncogenic signalling pathways, like Notch and p65Lck.
We previously reported that the over-expression of
Fbxo7 causes a late-onset T-cell lymphoma after the
adoptive transfer of p53 null haematopoietic stem cells
(HSCs) transduced to overexpress it. This indicated the
potential for increased Fbxo7 to be oncogenic in T cells
[29]. Given these data, and its capacity to directly bind
to Cdk6 and promote cyclin D3/Cdk6 complex forma-
tion [13], we reasoned that it would be an important
factor in T-cell biology. We report here that loss of
Fbxo7 expression in a mouse impairs both thymocyte
development and T-cell function. We demonstrate that
Fbxo7 expression has opposing roles in cell
proliferation within the T-cell lineage at different
stages, promoting proliferation of thymocytes within the
thymus, but restraining proliferation of activated T cells
in the periphery. This paradoxical activity of Fbxo7
indicates that the G1 phase circuitry during T-cell
development is differentially regulated from that of
mature T cells.
Materials and methods
Mice
All experimental animals were maintained in accordance
with animal licences approved by the Home Office and the
University of Cambridge’s Animal Welfare and Ethical
Review Body Standing Committee, and the ARRIVE
guidelines. All work described here was performed under
the Home Office licences PPL 80/2474 (expired 2016) and
PPL70/9001 (valid until 2021). Fbxo7LacZ mice (Fbx-
o7tm1a(EUCOMM)Hmgu C57BL/6J background) were
maintained in individually ventilated cages with unre-
stricted access to food and water, and heterozygous animals
were bred. WT and homozygous littermates were harvested
between 6–8 weeks, unless stated otherwise. Male and
female mice were both used for experiments.
For genotyping, crude genomic DNA extraction was
performed on ear punch biopsies. Tissue was digested
using a solution of 10% Chelex (BioRad), 100 lg/mL
proteinase K, and 0.1% Tween-20. One microliter of
supernatant was used in multiplex genotyping, with a
common 50 forward primer (CAGGATCAGG-
GAACGCCTGT) and different 30 reverse primers to
amplify the WT (TGCAGGGTGAATAGCACTTCC) or
the transgenic (CACAACGGGTTCTTCTGTTAGTCC)
allele. The reaction amplifying the WT allele produces a
197 bp product, whereas the reaction amplifying the
transgene produces a 362 bp product. The PCR consisted
of 35 cycles of 92, 62, and 72 C for 30 s each. Primers
pairs spanning an exon–exon boundary were used for qRT-
PCR of murine Fbxo7 using SYBR Green JumpStart Taq
Ready Mix (Sigma) on an iCycler thermocycler (BioRad).
Primers used were 50 (CGCAGCCAAAGTGTACAAAG)
and 30 (AGGTTCAGTACTTGCCGTGTG).
Tissue preparation
Spleens and thymuses were harvested and disaggregated by
passage through a 40 lm cell strainer, and splenocytes
subjected to RBC ammonium chloride lysis buffer to
remove excess RBCs. Cell density was determined by
trypan blue (Invitrogen) exclusion using a
haemocytometer.
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Flow cytometry and fluorescence activated cell
sorting (FACS)
Single cell suspensions of splenocytes and thymocytes
were stained with fluorescently labelled CD4-PE or CD4-
PECy7 (clone GK1.5) and CD8-APC (clone H35-17.2)
antibodies, for 30 min at 4 C in the dark, washed twice
with FACS buffer (PBS with 1% FBS), and CD4? or
CD8? positive cells analysed using Summit 4.3 software
(Beckman Coulter) on a Cyan ADP Analyser (Dako), or
sorted in PBS using a MoFlo FACS sorter (Dako). Sorted
cells were resuspended in the required media for culturing,
or lysed for immunoblotting. Cells were analysed using the
following gating strategy for thymocytes and splenocytes
(Supplementary Figs. 1A and B, respectively). Thymocytes
were also stained with antibodies to CD4-biotin and CD8-
biotin followed by Streptavidin-FITC, as well as antibodies
to CD44-PE (clone IM7), CD25-PECy7 (clone PC61.5),
and analysed or sorted using the following gating strategy
(Supplementary Fig. 1C). Collected cells were used for cell
cycle analysis or immunoblotting. All flow cytometry
antibodies were from eBiosciences. For TReg cells,
splenocytes were stained for CD3 and CD4, before being
fixed, permeabilised, and subjected to intracellular Foxp3
staining following the manufacturer’s recommendations
(eBioscience). Apoptosis was assayed by first staining cells
with antibodies to detect specific populations, washed once
in Annexin V binding buffer (10 mM HEPES, 140 mM
NaCl, 2.5 mM CaCl2, pH7.4), and then stained for Annexin
V? cells with Annexin V-Alexa Fluor 647, as per the
manufacturer’s recommendations (Catalogue no. A23204,
Invitrogen). Propidium iodide (PI) was also used at 2.5 lg/
mL to discriminate live cells from dead cells.
T-cell activation and cytokine analysis
For T-cell activation assays, lymphocytes in mixed
splenocyte suspensions were counted using a haemocy-
tometer and 2 9 105 cells plated per 96 well, in complete
RPMI media (RPMI with 10% heat inactivated (HI) foetal
bovine serum (FBS), 100 U/mL penicillin and strepto-
mycin, and 5 lM 2-mercaptoethanol (all Invitrogen))
supplemented with or without soluble 2 lg/mL anti-CD3e
(clone 145-2C11) and 2 lg/mL anti-CD28 (clone 37.51), to
activate T cells. Cells were incubated for 24, 48, and 72 h
in a humidified 37 C, 5% CO2 incubator. To assay for
activation markers, cells were analysed by flow cytometry
with antibodies to CD4-PE, CD8-APC, CD25-PECy7, and
CD69-FITC (clone H1.2F3, eBiosciences). See Supple-
mentary Fig. 1d and e for representative FACS plots. For
cytokine analysis, CD4? T cell from spleen were FACS
sorted and plated as above. Cells were incubated for 24 and
48 h, and then supernatants collected for cytokine analysis
using ELISA assays for IL-2, IFN-c, as per the manufac-
turer’s instructions (eBioscience).
Cell cycle analysis
For carboxy fluorescein succinimidyl ester (CFSE) stain-
ing, splenocytes (3 9 106 cells/mL) were incubated with
1 lM CFSE (Invitrogen) in PBS for 15 min in a humidified
37 C, 5% CO2 incubator. Cells were washed twice with
PBS supplemented with 10% FBS and resuspended in
complete RPMI media. CFSE labelled cells (2 9 105/well
in 96-well plates) were seeded in a final volume of 200 lL
complete RPMI media with soluble anti-CD3 and anti-
CD28 as described above, and cultured for 48 and 72 h.
Cells were analysed for CFSE dilution using flow cytom-
etry. For cell cycle analysis using PI, thymocytes were
FACS sorted, and stained as described in [15], and anal-
ysed by flow cytometry.
Statistical analyses
Statistical differences between mutant and WT were calcu-
lated using Student’s two-tailed t tests with a significant
cutoff of p\ 0.05. Data are presented as mean ± standard
deviation. On graphs, *p\ 0.05, **p\ 0.01, ***p\ 0.001.
Cell lysis
Sorted cells or whole thymuses were lysed in RIPA buffer
(50 mM Tris–HCl pH 7.6, 150 mM NaCl, 1% NP-40, 0.1%
SDS, 0.1% Na deoxycholate, 19 protease inhibitors,
1 mM PMSF, 10 mM sodium fluoride, 1 mM sodium
orthovanadate) (all from Sigma), and incubated on ice for
30 min with occasional vortexing. Cell debris was pelleted
by centrifugation at 16,000g for 10 min at 4 C. Cell
lysates were collected and protein concentration deter-
mined using the BCA method in a 96-well plate (Pierce).
Protein samples were diluted in lysis buffer to the desired
concentration, ensuring equal protein concentrations across
all samples.
Immunoblotting
Protein samples were mixed with equal volumes of 29
Laemmli buffer and denatured by incubating at 95 C for
5 min. Proteins were then separated using Tris–Glycine
SDS polyacrylamide gel electrophoresis (SDS-PAGE), and
transferred onto polyvinylidene fluoride (PVDF) mem-
brane (Millipore) using a semi-dry transfer system
(Biorad). Membranes were blocked for 1 h with 5% non-
fat, milk powder/PBS-Tween 20 (0.05%) (PBS-T), and
then probed with primary antibody overnight at 4 C in 5%
non-fat, milk powder/PBS-T. Membranes were washed in
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PBS-T and incubated in the appropriate HRP-conjugated
secondary antibody in 5% non-fat, milk powder/PBS-T
followed by further washes, and detection of HRP bound
protein using enhanced chemiluminescence (ECL, GE
Healthcare) and exposure onto X-ray film (Konica Min-
olta). Signal was quantified and normalised using the
ImageJ software (NIH, Maryland).
Antibodies
Antibodies for western blotting were used as described in
[16], as well as anti-cleaved caspase 3 (9664S), anti-
phospho pRb Ser780 (8180S), and anti-phospho pRb
Ser807/811 (9308S), all from Cell Signalling Technolo-
gies, and anti-GAPDH (G9545) and anti-c-tubulin (T6557)
both from Sigma-Aldrich.
Results
Defective thymocyte development in Fbxo7LacZ/LacZ
mutant mice
The generation of Fbxo7LacZ mice has been described
previously [16], and a schematic of the transgene is shown
in Fig. 1a. Expression of Fbxo7 is disrupted by the pres-
ence of the LacZ gene, with a preceding splice acceptor
site, between exons 3 and 4 of Fbxo7. The identification of
mice with the LacZ insertion was confirmed by multiplex
PCR (Fig. 1b) where a common forward primer (half
arrows, Fig. 1a) amplifies a 197 base pair product with a
reverse primer to WT genomic sequences, or a 362 base
pair product with a reverse primer to sequences in the
transgene. Mice with homozygous inheritance of an Fbx-
o7LacZ (mutant) allele consistently had visibly smaller
thymuses (n = 45) compared to WT mice (Fig. 1c), which
were on average 25% of the mass of WT (Fig. 1d). This
phenotype was fully penetrant, and this was quantified as
an 80% reduction in cell number (Fig. 1e). Homozygous
Fbxo7LacZ mice have approximately 80–90% reduction in
Fbxo7 mRNA expression in many tissues, such as liver,
spleen, and cerebellum, as shown by qRT-PCR analysis
[15]. In the thymus, no Fbxo7 message is detected by qRT-
PCR analysis [15], and we could not detect any protein
expression by immunoblotting of Fbxo7LacZ/LacZ lysates
from whole thymuses (Fig. 1f). Haematoxylin and eosin
staining of thymuses harvested from littermate-matched
WT and Fbxo7LacZ/LacZ mice showed intact medulla and
cortical thymic compartments with no gross changes in
their anatomical structure (Fig. 1g), arguing against pre-
mature involution as a cause of hypoplasia.
To investigate the cellular deficiencies in the thymus,
the total cell numbers at all T-cell developmental stages
were quantified. Single cell suspensions from thymuses
from WT and Fbxo7LacZ/LacZ littermates were stained for
CD4 and CD8 (double negative (DN), double positive
(DP), and single positive either for CD4? or CD8?)
(Fig. 1h), or for CD25 and CD44 to identify developmental
stages within the CD4 and CD8 DN population [CD25-
CD44? (DN1), CD25? CD44? (DN2), CD25? CD44-
(DN3), and CD25- CD44- (DN4)] (Fig. 1i). The absolute
cell numbers were significantly reduced at all develop-
mental stages (Fig. 1h, i). The relative proportions at each
stage of T-cell differentiation were also determined, and
we observed a statistically significant 0.73-fold increase in
the total DN fraction (Fig. 1j), such that this fraction
accounted for 9.5% of total thymocytes in mutant mice
compared to 5.5% in WT mice. No significant differences
were seen in the proportions of the DP or SP populations
(Fig. 1j). To investigate whether a particular DN stage was
affected, the proportion of cells at each DN stage in thy-
muses from mutant and WT mice were analysed. The
percentage of DN1 cells was significantly increased in
mutants compared to WT (0.41-fold increase), whereas the
percentage of DN4 cells was reduced significantly (0.22-
fold decrease) in mutants compared to WT (Fig. 1k). This
proportional increase in DN1 cells in the mutant mouse
must contribute to the statistically significant increase in
the DN populations compared to DP and SP populations
(Fig. 1j), since the DN2/DN3 proportions are similar and
DN4 is reduced in the mutant thymuses (Fig. 1k). Thus,
among DN populations in Fbxo7LacZ/LacZ mice, there were
increased DN1 cells and fewer DN4, which may stem from
changes in proliferation and/or apoptosis. We noted that
when thymuses from mice older than 10 weeks were
analysed, the proportions at individual DN stages were
unchanged (Supplementary Fig. 2a), indicating that these
defects can be compensated for over time.
Reduced numbers of the early thymic progenitors
(ETPs) in mutant mice
A possible cause for thymic hypoplasia might be insuffi-
cient seeding of the thymus or defects in the survival or
development of ETPs after seeding. To address this, we
quantified, by flow cytometry, the number and proportion
of bone marrow (BM)-derived ETPs, identified as c-Kit?
within the DN1 population (CD44? CD25- CD4- and
CD8-) cells. A significant reduction in the percentage
(0.45-fold) and absolute number (0.76-fold) of ETPs was
observed in Fbxo7LacZ/LacZ mice compared to WT (Fig. 2a,
b). Although these data might suggest a BM insufficiency,
a previous analysis of haematopoietic progenitor popula-
tions in the BM of Fbxo7LacZ/LacZ mice showed no
significant changes in the percentages of LMPPs (Lin-
Sca-1? c-Kit? CD34? and Flt3?) or CLPs (Lin- IL-7Ra?
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and Flt3?) compared to WT [15]. These data argue against
a depleted progenitor pool in the BM as a cause of hypo-
plasia, but demonstrate the presence of fewer ETP cells in
the thymus of mutant mice. This might occur due to
reduced seeding of the thymus or decreased viability of
ETPs within the thymus.
0
20
40
60
80
100
DN1 DN2 DN3 DN4
%
 o
f D
N
 th
ym
oc
yt
es
c
f
0
20
40
60
80
100
Th
ym
ic
 c
el
lu
la
rit
y 
(x
10
6 )
**
WT mutant
h
0
50
100
150
DN DP CD4 CD8
# 
of
 c
el
ls
 (x
10
6 )
*
*
* * 0
1
2
3
4
5
6
DN1 DN2 DN3 DN4
# 
of
 c
el
ls
 (x
10
6 )
* * * *
i
d
g
j k
0
20
40
60
80
100
DN DP CD4 CD8
%
 o
f t
ot
al
 th
ym
oc
yt
es
*
WT mutant
WT mutant WT mutant
WT mutant WT mutant
Gapdh 40
Whole thymus
80
50
Fbxo7
* *
a b
500
400
300
200
0
20
40
60
80
Th
ym
us
 m
as
s 
(m
g)
***
e
WT mutant
3 4 5
WT allele
Targeted
allele
2a2b 3 4 5 6 7 8 91a1b
3 4 5FRT FRT loxP loxPloxP
SA pApA
LacZ neo
WT mutant
Fig. 1 Fbxo7LacZ/LacZ mice
have thymic hypoplasia.
a Schematic of murine Fbxo7
locus with WT and targeted
allele, Fbxo7tm1a(EUCOMM)Hmgu,
showing LacZ/neo insertion
with splice acceptor (SA) site
and poly-A tails (pA). Primers
used for multiplex genotyping
are shown (half arrows).
b Multiplex PCR reaction
showing amplification of WT
(197 bp) and mutant (362 bp)
alleles in WT, heterozygous
(het), and homozygous LacZ
(mutant) mice. The same
forward primer is used in both
reactions. c Photograph of
thymuses from 2- to 4-month-
old littermate WT and
Fbxo7LacZ/LacZ mutant mice,
from 3 L. d Quantification of
thymus weight from 2- to
4-month-old mice (n = 4 WT
and n = 8 mutant mice from
4 L). e Total thymic cellularity
of WT (n = 6) and Fbxo7LacZ/
LacZ (n = 5). f Lysates made
from thymuses from WT,
heterozygous, and homozygous
Fbxo7LacZ mice were analysed
by immunoblotting for Fbxo7
and actin (n = 1). g H&E-
stained sections of WT and
Fbxo7LacZ/LacZ thymus showing
medullary (pink) and cortical
(blue) compartments. Scale bars
200 lm (n = 3 from 2 L).
h Total cell number of indicated
populations in WT (n = 6) and
Fbxo7LacZ/LacZ (n = 5)
thymuses. i Total cell number at
each DN stage in WT (n = 7)
and Fbxo7LacZ/LacZ (n = 6)
thymuses. j, k Graphs showing
percentages of cells in each
thymocyte subpopulation from
WT (n = 21) and Fbxo7LacZ/
LacZ (n = 18) thymuses. Data
are represented as mean ± SD,
*p\ 0.05, **p\ 0.01,
***p\ 0.001
Opposing effects on the cell cycle of T lymphocytes by Fbxo7 via Cdk6 and p27
123
Increased apoptosis and reduced proliferation
of mutant DN thymocytes
We next investigated whether changes in the rates of
apoptosis and/or proliferation within thymic subsets might
account for the observed differences in mutant mice. To
test this, thymocytes at all developmental stages were
stained for Annexin V (Fig. 2c). Flow cytometry analysis
showed a 1.74- and 0.87-fold increase in Annexin V
staining at the DN1 and DN4 stages, respectively, in
mutant cells compared to WT. There were no significant
differences in Annexin V? cells at the other DP, CD4 SP,
and CD8 SP stages (Supplementary Fig. 2b). To further
test this finding, immunoblotting of whole cell extracts of
thymuses for cleaved caspase 3 showed that mice
homozygous for the Fbxo7LacZ allele had the highest levels
(Fig. 2d), supporting the idea that apoptosis levels
increased when Fbxo7 expression was reduced.
We also tested whether the proliferation of thymocytes
was altered. As an indicator of cell cycle phase, the DNA
content was analysed by staining sorted DN populations
with PI. Cells in G0/G1 phase (2 N DNA) and S/G2/M
phases ([2 N DNA) were quantified and expressed as a
percentage for each DN population. There was no
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(n = 1). e Graph showing
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Data show mean of four
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*p\ 0.05, **p\ 0.01. f,
g Representative western blot of
lysates from FACS sorted DN1,
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from four pooled WT and
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showing cell cycle regulatory
proteins (f), or phosphorylated
pRb (g). GAPDH and Ponceau
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loading control as indicated.
These experiments were
repeated twice
S. P. Patel et al.
123
statistically significant change in the percentage of cycling
cells at the DN1 and DN2 stages. However, cycling cells
(with[2 N DNA content) were significantly reduced by
29.5% in the DN3 population and by 59.5% in the DN4
population in mutant mice compared to WT (Fig. 2e).
These data indicated that Fbxo7 is important for the pro-
liferative burst that occurs at the DN3 and DN4 stages.
Taken together, these data indicate that Fbxo7 loss causes
deficiencies at multiple stages, including at the earliest
DN1 stage, where we observed reduced ETP numbers and
increased apoptosis, reduced proliferation at the DN3
stage, and both increased apoptosis and reduced prolifer-
ation at the DN4 stage in mutant mice.
Lack of Cdk6 expression in Fbxo7LacZ/LacZ
thymocytes
Fbxo7 promotes the assembly of D-type cyclins with Cdk6
[13, 14], and thymocyte proliferation has been shown to be
crucially dependent on Cdk6 [25, 26, 30]. To determine
whether the absence of Fbxo7 affected the expression of
these G1 cell cycle regulators, DN1/3/4 thymocytes from
WT and Fbxo7LacZ/LacZ mutant mice were harvested, and
cell lysates analysed by immunoblotting (Fig. 2f). The
numbers of DN2 cells recovered were insufficient for
analysis, due to the reduced cellularity of mutant thymuses
and small percentage of DN2 cells. The most obvious
difference seen was that Cdk6 was undetectable in samples
from mutant mice, and there was also a reduction in Cdk2
levels compared to WT samples. In addition, in mutant
DN4 thymocytes, there were increased levels of cyclins D2
and D3 compared to WT, but in DN1 and DN3 cells,
D-type cyclin levels were similar (Fig. 2f).
To further investigate the molecular effect of the loss of
Cdk6, we tested for its activity in DN populations by
immunoblotting using phospho-specific antibodies for pRb
phosphorylation at Ser780, as modification at this residue is
used as a marker of cyclin D/Cdk6 activity. Equal numbers
of DN1/3/4 cells from WT and mutant mice were har-
vested, and cell lysates were immunoblotted. All DN
thymocytes from WT mice had readily detectable phospho-
Ser780 pRb in contrast to DN thymocytes from mutant
mice where none was detected (Fig. 2g). These data indi-
cate that Cdk6 activity was absent in the tested DN
populations of Fbxo7LacZ/LacZ mutant mice, and support the
idea that Fbxo7 promotes cyclin D-Cdk6 activity, which
promotes the proliferation of immature thymocytes.
Fbxo7LacZ/LacZ mice have fewer CD4? and CD8? T
cells in the periphery
A lack of Fbxo7 expression resulted in significantly fewer
cells differentiating to the SP stages within the thymus
(Fig. 1h). To assess the effect on mature T cells in the
periphery, the percentage and absolute numbers of
peripheral CD4? and CD8? T cells were determined by
counting T cells in the spleen. Fbxo7LacZ/LacZ mice have
significantly enlarged spleens due to extramedullary hae-
matopoiesis; however, splenic cellularity of mutant mice
was comparable to WT littermates after the lysis of RBCs,
indicating that the increase is due mostly to erythroid lin-
eage cells [15]. Mature T cells were stained using
antibodies to CD4 and CD8 surface markers and analysed
by flow cytometry. There were 0.74- and 0.77-fold reduc-
tions in the proportions of CD4? and CD8? T cells in
spleens from mutant mice compared to WT (Fig. 3a). The
absolute number of CD4? and CD8? T cells was also
significantly reduced, in mutant mice (Fig. 3b). These data
showed a significant reduction in peripheral CD4? and
CD8? effector T cells of Fbxo7LacZ/LacZ mice, consistent
with the reduced cellularity observed in the thymus.
Within the CD4 population, we also tested whether
mutant mice had altered numbers of Foxp31 regulatory T
cells (TReg) which suppress the immune response. Spleno-
cytes were harvested and stained for CD4, CD25, and Foxp3.
Although the number of CD41 Foxp31 cells was the not
significantly different between WT and mutant mice, pro-
portionally, there was a statistically significant 0.75-fold
increase in CD4? Foxp3? TReg cells, due to the overall
decrease in effector T cells in mutant mice (Fig. 3c, d).
CD4? and CD8? T cells lacking Fbxo7 showed
delayed activation
To assess the role of Fbxo7 in T-cell activation in the
mature CD4? and CD8? T-cell populations, we assayed for
the expression of surface markers CD69 and CD25 after
TCR stimulation with soluble antibodies to CD3 and
CD28. Equal numbers of T cells were analysed, and both
CD4? and CD8? T-cell populations from mutant mice
showed significantly fewer double positive cells (16%
fewer for CD4? and 6% for CD8? T cells) compared to
WT at 24 h after TCR stimulation, (Fig. 4a, Supplementary
Fig. 1d, e). At 48 h post-stimulation, the percentages of
WT and mutant CD4? and CD8? T cells expressing both
activation markers were comparable. In the absence of
stimulation by CD3/CD28, no CD25? CD69? cells were
detected. Thus, both CD4? and CD8? T cells show delayed
activation in the absence of Fbxo7, indicating a require-
ment for Fbxo7 function in the timely activation of T cells.
Fbxo7-deficient T cells expand more rapidly
after TCR engagement
T-cell activation is followed by rapid increases in cell
number, with cell doubling times reported to be as little as
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4.5 h [31], and differentiation into effector T cells. We next
tested whether proliferation was altered in mutant cells.
Splenocytes were stimulated with soluble antibodies to
CD3 and CD28, and the percentages of CD4? and CD8? T
cells were monitored over 3 days. At the outset, CD4? T
cells comprised 16.4% of WT and 5.9% of mutant
splenocyte cultures (Supplementary Fig. 2c). After 24 h,
this number was largely unchanged in both cultures.
However, by 72 h, the percentage of CD4? T cells in WT
cultures was 13.1% and comparable to the percentage of
CD4 cells in mutant cultures of 11.4%. When the fold
change in absolute cell number was calculated, mutant
CD4? T cells had expanded by 1.27- and 2.06-fold at 48
and 72 h compared to the starting number, whereas WT
CD41 T cells expanded 1.27 fold by 48 h but was back to
day 0 numbers by 72 h (Fig. 4b, left). Thus, the significant
difference between the numbers of WT and mutant CD4
cells observed at the start of the assay was lost by 72 h due
to the more rapid expansion of mutant CD4? cells (Sup-
plementary Fig. 2c).
A similar analysis was performed for CD8?T cells. At day
0, there were significantly fewer CD8? T cells in mutant
cultures: 2.6% compared to 9.2% in WT samples (Supple-
mentary Fig. 2d). By 72 h, Fbxo7LacZ/LacZ and WT cultures
contained 25.9 and 34.7% CD8? T cells, respectively,
showing that bothWTandFbxo7LacZ/LacZCD8cells expanded
robustly. However, when the fold change in absolute cell
number was calculated,Fbxo7LacZ/LacZ cultures had expanded
to a much greater extent over 72 h (Fig. 4b, right). At 48 and
72 h, WT cells expanded 2.3- and 4.7-fold compared to 2.9-
and 10.6-fold expansion of mutant cells at the same time
points.Notably, despite their greater expansion, quantification
of the absoluteCD4andCD8 cell number in activated cultures
over the course of the experiment showed that the number of
mutant T cells did not exceed that of WT T cells (Supple-
mentary Fig. 2e, f), These data demonstrated that activated
CD4? and CD8? T cells lacking Fbxo7 increased in numbers
significantly more than WT cells.
Fbxo7LacZ/LacZ T cells cycle more rapidly
after activation
To investigate the observed greater increase in the numbers
of mutant T cells following activation, we tested whether
activated T cells showed changes in their rates of prolif-
eration. After treatment with RBC lysis buffer, equal
numbers of WT and mutant splenocytes were first labelled
with a fluorescent dye CFSE and then incubated with CD3
and CD28 antibodies. Flow cytometry was used to monitor
CFSE dilution as an indicator of cell divisions at 48 and
72 h post-activation in both CD4? and CD8? cells
(Fig. 4c). At 48 h, 74.6% of mutant CD4? T cells had
undergone 3 or more cell divisions compared to 36.9% in
WT samples (Fig. 4c, top row), and by 72 h, 77.7% of
CD4? mutant T cells had divided 5 or more times com-
pared to 35.3% in WT cultures (Fig. 4c, bottom row).
Similarly, at 48 h, 94.2% of CD8? mutant T had divided 3
or more times compared to 57.8% in WT samples (Fig. 4c,
top row), and by 72 h, 99.7% CD8? mutant T cells had
undergone 5 or more cell divisions compared to 83.1% in
WT cultures (Fig. 4c, bottom row). These data show that
after activation, Fbxo7 mutant T cells cycle significantly
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faster than WT cells, and indicate an anti-proliferative role
for Fbxo7 in the proliferation of activated T cells.
Increased IL-2 and IFN-c production by Fbxo7LacZ/
LacZ CD41 T cells
Upon TCR activation, naive CD4? T cells may differen-
tiate into one of several Th lineages, each defined by their
pattern of cytokine production and function. We tested for
Th1 and Th2 cytokines secreted by isolated WT and mutant
CD4? T cells after TCR activation with soluble antibodies
to CD3 and CD28 molecules. At 24 and 48 h, after TCR
activation, supernatants from T cells cultures were col-
lected and cytokines concentrations were measured using
ELISAs. Levels of Th1 and Th2 cytokines were assayed to
give an overview of effector functions of CD4? T cells. At
24 h, the IL-2 concentration in mutant CD4? T samples
was comparable to WT samples, and at 48 h, the IL-2
concentration was on average 325 pg/mL in mutant CD4?
T-cell samples compared to 171 pg/mL in WT samples, a
1.9-fold increase (Fig. 4d). Similarly, at 48 h post-stimu-
lation, mutant CD4 cells produced 1093 pg/mL of IFN-c
compared to 501 pg/mL in WT cultures, representing a
2.2-fold increase, which was statistically significant
(Fig. 4e). These results indicated that mutant CD4? T cells
produced a Th1 cytokine response similar to WT, sug-
gesting that subsequent activation of other immune cells,
such as macrophages, and CD8? T cells would be possible
in Fbxo7LacZ/LacZ mice. The levels of IL-4 and IL-10,
indicative of a Th2 response, were also determined, and
both were similar in WT and mutant samples (data not
shown). These results showed that activated mutant CD4?
T cells were capable of producing both Th1 and Th2
cytokines. The approximate twofold increase in the pro-
duction of IL-2 and IFN-c despite overall fewer cell
numbers may be a due to the more rapid proliferation of
mutant CD4 cells upon activation.
Increased apoptosis in resting and activated mutant
CD4? and CD8? T cells
Since mutant T cells expanded more rapidly than WT cells
after activation, we tested whether the capacity to undergo
apoptosis was inhibited which might also contribute to the
observed increased expansion upon activation. To deter-
mine the percentage of T cells undergoing apoptosis, WT
and mutant splenocytes were stimulated as above. At 48
and 72 h of TCR stimulation, cells were removed and co-
stained with antibodies to CD4 and CD8 along with
Annexin V (Fig. 5a, b). Interestingly, there were signifi-
cantly more apoptotic mutant CD4? T cells: 43.3%
compared to 12.8% for WT cultures at 48 h, and 30.6%
compared to 9.9% at 72 h, reflecting a 2.4 and 2.1 fold
increase, respectively, in stimulated mutant CD4? cells
(Fig. 5a). In contrast, 48 h post-stimulation, 9.5% of
mutant CD8? T cells were Annexin V1 compared to 5.3%
cells in WT samples, a difference which was not statisti-
cally significant (P = 0.051). At 72 h, both cultures had
approximately 5% Annexin V1 cells (Fig. 5b). Thus,
mutant CD4? T cells, but not CD8? T cells, showed sig-
nificantly increased levels of apoptosis after activation, and
demonstrate that apoptosis induction was not suppressed in
mutant T cells. The higher rates of apoptosis in CD4?
compared to CD8? cells (*13 vs. 5% for WT cultures)
may contribute to the more limited expansion of CD4 cells
relative to CD8 cells observed in culture (Supplementary
Fig. 2e, f).
Resting T cells are thought to be more resistant to apop-
tosis than activated T cells. To investigate if increased
apoptosis was also observed in resting T cells, unstimulated
splenocytes from mutant and WT mice were also tested for
staining with Annexin V (Fig. 5c). Flow cytometry analysis
showed significantly greater numbers of Annexin V? mu-
tant CD4? and CD8? T cells. There was a 0.93-fold increase
in the number of Annexin V? cells: 27.2% mutant CD4?
cells compared to 14.1% in WT mice, and about a 0.4-fold
increase in Annexin V? mutant CD8? cells: 54.9% com-
pared to 39.4% inWTmice (Fig. 5c). These results indicated
that resting T cells in the periphery of mutant mice undergo
higher levels of apoptosis, which suggests that they may a
have shorter lifespan. This may contribute to the decreased
number of mature T cells present in the periphery, and sug-
gests that Fbxo7 may regulate molecular pathways
governing the survival of resting T cells.
Fbxo7LacZ/LacZ T cells have less p27
p27 is a critical mediator of T-cell quiescence, and TCR
crosslinking causes both transcriptional and translational
down-regulation of p27, leading to increased cyclin
E/Cdk2 and A/Cdk2 activity, which promotes S phase
entry [32]. We hypothesized that one mechanism to
account for the more rapid cycling and increased apoptosis
seen in mutant T cells might be reduced p27 levels. CD4?
and CD8? T cells were isolated from spleens, and equal
numbers of cells from each population were lysed. Protein
lysates were immunoblotted, and both CD4? and CD8?
mutant T cells showed reduced p27 levels (Fig. 5d). One
consequence of reduced p27 expression would be a reduced
inhibitory threshold for the activation of late G1 and S
phase cyclin E/Cdk2 and A/Cdk2 activities. This would
facilitate cell proliferation in activated T cells or directly
induce apoptosis in quiescent cells, if appropriate sec-
ondary stimuli were not present. To test whether Cdk
activity was increased in quiescent cells, phospho-specific
antibodies to detect pRb modification were used to probe
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cell lysates from resting CD4? T cells purified as in 5d. We
observed increased signals for phosphorylation at Ser780
and at Ser807/811, indicating inactivation of pRb (Fig. 5e).
Interestingly, Cdk6 expression was similar in mutant and
WT cells, indicating that in peripheral T cells, Fbxo7 is not
required to stabilize its expression or its activation by
D-type cyclins. These data indicate that increased prolif-
eration and apoptosis in Fbxo7LacZ/LacZ T cells may be
explained by reduced p27 expression and increased overall
Cdk activity, but not levels.
Discussion
Our data on the defects within the T-cell lineage that arise
due to the absence of Fbxo7 expression reveal its critical
activities at different stages of development and function.
Most striking is the fact that Fbxo7 has opposing roles in
regulating cell cycle proliferation in a single cell type,
stemming from its ability to act as a scaffold and stabilizer
of the levels of Cdk6 and p27, whose functions appear to
predominate at different times in T-cell biology [13–16].
During the development of T cells in the thymus, Fbxo7
appears to be required for proliferation at the DN3/DN4
stages, yet in the periphery, it functions to restrain prolif-
eration after T-cell activation, as evidenced by the very
rapid cell division of mature T cells after they are CD3/
CD28 stimulated.
The roles of Cdk6 and p27 within the thymus have been
independently tested using knock-out mouse models. The
previously reported Cdk6 null mouse models both have
reduced cellularity in their thymus [25, 30]. Deficiencies in
cell number disproportionately decreased the immature
thymocyte populations; however, small increases in thymic
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SP CD4? and CD8? cell numbers were observed. DN2 and
DN3 cells showed reduced proliferation, and reduced
apoptosis was observed at DN3, DN4, and SP cells. In the
periphery, mature Cdk6 null T cells were slower to pro-
liferate after mitogenic stimulation, although overall
numbers of peripheral T lymphocytes were comparable to
WT. These studies indicate that Cdk6 regulates the dif-
ferentiation of thymocytes and the proliferative response of
activated T lymphocytes. Fbxo7-deficient mice mimicked
certain phenotypes of the Cdk6 null mouse, most obvious
being that mutant DN cells showed no Cdk6 expression or
any evidence of Cdk6 activity as shown by the absence of
Ser780 pRb, which is the likely defect underlying the
failure of DN3/DN4 cells to proliferate in mutant mice.
Cyclin D3 KO mice also show proliferative defects at the
DN3/DN4 stages [27]. Both cyclin partners D2 and D3
were detected in mutant mice, so the lack of Cdk6 was not
due to their absence. Indeed, the inability to detect Cdk6 in
mutant cells may be due to its inability to assemble with
cyclin D2 and D3 in the absence of Fbxo7, which causes
Cdk6 destabilisation. Cyclins D2 and D3 may interact with
the other Cdks, 4 or 2, neither of which interact with Fbxo7
[13], but neither of which can substitute for Cdk6 activity
at this critical stage in T-cell development [26, 30]. In
contrast to the Cdk6 null and Fbxo7LacZ mouse models, the
three p27 KO mouse models demonstrate enlarged thy-
muses, with no alterations to T-cell development [33–35],
suggesting that mis-regulation of p27 plays a minimal role
in the thymic phenotype observed in Fbxo7LacZ mice. An
additional, unique defect we uncovered within the Fbxo7-
deficient thymus was at the ETP/DN1 stage, where we
observed decreased numbers of ETPs and also increased
apoptosis of DN1 cells. These data indicated multiple
defects in T-cell development at the earliest settling of the
thymus by precursor cells, and their later proliferative
expansion stages at the DN3/DN4 stages, along with
increased apoptosis at the DN4 stage. The absence of Cdk6
at the DN3 and DN4 stages is likely to underlie the failure
of these cells to expand; however, Cdk6 was not detected at
the DN1 stage, and is, therefore, unlikely to account for the
defects then.
Within the spleen, Fbxo7LacZ/LacZ mice had fewer
mature CD4? and CD8? T cells, which displayed delayed
activation, similar to Cdk6 null cells [25, 26], yet faster
proliferation upon activation, which is likely to be due to
decreased levels of p27 and the inactivation of pRb seen
in these cells. Indeed, the latter phenotype is akin to that
of p27 KO T cells, which have been shown to have
increased numbers of cells in S phase, higher cyclin E
activated kinase activity, and increased responsiveness to
mitogens [33]. However, these cells also showed no
changes in their levels of apoptosis, suggesting that their
increased Cdk activity leads to increased cell proliferation
and hyperplasia rather than cell death [33]. Both naı¨ve
CD4? and CD8? T cells and activated CD4? T cells from
Fbxo7-deficient animals showed increased levels of
apoptosis, which suggests that aberrant cell signalling,
rather than increased proliferation, is leading to increased
cell death. Notably, since CD8? T cells proliferate faster
and more robustly than CD4? T cells, yet do not show
increased apoptosis levels, this argues against enhanced
proliferation as the cause of apoptosis. An alternate pos-
sibility is that increased proliferation contributes to
increased apoptosis, but mutant CD8? T cells lacking
Fbxo7 expression were protected from death due to the
presence of growth factor(s) in the cultures providing
survival signals. For instance, IL-2 secreted by activated
CD4? T cells and to lesser extent by activated CD8? T
cells is a key regulator of T-cell apoptosis. IL-2 levels
together with the intensity of antigenic stimulation influ-
ence the viability of activated T cells [36]. A third
possibility is that Fbxo7LacZ/LacZ CD8? T cells may also
undergo increased levels of apoptosis, but the effect is
offset by their high proliferation rate.
Overall, Fbxo7LacZ/LacZ mice show a dramatically
reduced number of peripheral T cells which show delayed
activation. Moreover, within their significantly reduced
CD4 T-cell population, they show a proportional increase
in TReg cells, which may limit their immune responses.
However, once activated both CD4 and CD8 cells prolif-
erate robustly, despite the higher levels of apoptosis of
CD4 cells. In addition, activated Fbxo7-deficient CD4?
cells were capable of producing both Th1 and Th2 response
cytokines and produced *twofold more IL-2 and IFN-c.
Collectively, these attributes suggest that these mice may
be compromised in their immune responses. In support of
this idea, we noted the results of a Salmonella typhimurium
challenge using 6-week-old C57BL/6-Fbx-
o7tm1a(EUCOMM)Wtsi mice performed by the Mouse
Phenotyping Consortium. Their study showed that these
mice had a significantly increased susceptibility to Sal-
monella-induced morbidity, with significantly higher
bacterial counts in the spleen, liver, and caecal contents of
Fbxo7-deficient mice compared to WT (Wellcome Trust
Sanger Institute, Cambridge UK; personal communication)
[37].
In addition to the extensive perturbations in the pro-
duction and function of T cells caused by the loss of Fbxo7,
our findings demonstrate the differential regulation of the
G1 phase of the cell cycle in this cell lineage. These
effects, which differ from the phenotypes of the single
Cdk6 or p27 KO mouse models, reflect the capacity of
Fbxo7 to act as a cell cycle regulator that directly impacts
on both proteins that clearly provide non-redundant and
critical functions at different stages in the development and
functioning of T cells.
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